pre-capillary pulmonary hypertension

Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular disease characterized by abnormally high blood pressure in the small arteries of the lungs. It can result from various factors, including genetic predispositions, autoimmune diseases, heart conditions, lung disorders, and exposure to certain medications or toxins. If left untreated, PAH can lead to right ventricular hypertrophy, heart failure, and potentially fatal outcomes.

Symptoms of PAH may encompass shortness of breath, fatigue, chest pain, fainting, and swelling in the legs. These symptoms can progressively worsen, impacting the patient's daily activities and work capabilities. For a definitive diagnosis of PAH, physicians may recommend a range of diagnostic tests, such as chest X-rays, electrocardiograms, echocardiograms, pulmonary function tests, blood tests, and cardiac catheterizations.

The objectives of treating PAH are to alleviate symptoms, enhance the quality of life, and slow the disease's progression. Treatment options may encompass pharmacological therapy, oxygen therapy, surgical interventions like lung transplantation, and lifestyle modifications, including smoking cessation, weight management, and regular exercise. Patients should adhere to their doctor's recommendations, engage in regular follow-ups, and vigilantly monitor any changes in their symptoms. Timely medical consultation is crucial if the condition deteriorates or new symptoms emerge.